October 18, 2021
The University of Tsukuba and TNAX team discovered a target that ameliorates post-ischemic stroke neurological damages(Press Release).
May 17, 2021
University of Tsukuba and TNAX Biopharma Corporation identified an antibody which ameliorates complications associated with GVHD, and findings were published in Proc Natl Acad Sci USA(Press Release).
November 29, 2019
Series A2 funding closed.（jafco, mucap, nissay-cap）
February 25, 2019
Our article was on the on line magazine “Nikkei Bitotech”.（press release）
November 30, 2018
Series A funding closed.（jafco, mucap, nissay-cap）
November 30, 2018
TNAX Biopharma was authorized as a startup originated from University of Tsukuba.(press release, university of Tsukuba)